# Fernando C. Fervenza

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fernando-c-fervenza/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,192 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 98 |
| i10-index | 323 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5073207965 |
| ORCID iD | 0000-0002-9952-209X |
| Works | 582 |

## Researcher papers

Showing 12 of 48.

- [Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis/)
- [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdigo-2021-clinical-practice-guideline-for-the-management-of-glomerular-diseases/)
- [Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study](https://scholariq.org/papers/efficacy-and-safety-of-rituximab-in-patients-with-active-proliferative-lupus/)
- [The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification](https://scholariq.org/papers/the-oxford-classification-of-iga-nephropathy-rationale-clinicopathological/)
- [The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility](https://scholariq.org/papers/the-oxford-classification-of-iga-nephropathy-pathology-definitions-correlations/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis](https://scholariq.org/papers/efficacy-of-remission-induction-regimens-for-anca-associated-vasculitis/)
- [Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference](https://scholariq.org/papers/atypical-hemolytic-uremic-syndrome-and-c3-glomerulopathy-conclusions-from-a/)
- [C3 glomerulopathy: consensus report](https://scholariq.org/papers/c3-glomerulopathy-consensus-report/)
- [Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy](https://scholariq.org/papers/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy/)
- [Membranoproliferative Glomerulonephritis — A New Look at an Old Entity](https://scholariq.org/papers/membranoproliferative-glomerulonephritis-a-new-look-at-an-old-entity/)
- [The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group](https://scholariq.org/papers/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.